CIK 0001728117 · Non-accelerated filer<br>Smaller reporting company
Gossamer Bio, Inc.
Sign in to watch- Ticker
- GOSS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 475461709
- Phone
- (858) 684-1300
- Business address
- 3115 MERRYFIELD ROW, SUITE 120, SAN DIEGO, CA, 92121
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-04 | Christian Waage EVP, Tech Ops and Admin | Grant or award · Stock Option (Right to Buy) | +440,000 | 440,000 | ||
| 2025-03-04 | Smith Robert Paul JR Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +572,000 | 572,000 | ||
| 2025-03-04 | Aranda Richard Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +572,000 | 572,000 | ||
| 2025-03-04 | Giraudo Bryan COO/CFO | Grant or award · Stock Option (Right to Buy) | +638,000 | 638,000 | ||
| 2025-03-04 | Hasnain Faheem President & CEO | Grant or award · Stock Option (Right to Buy) | +1,540,000 | 1,540,000 | ||
| 2024-06-24 | Aranda Richard Chief Medical Officer | Sale | −1,908 | $0.66 | $1K | 196,891 |
| 2024-06-21 | Hasnain Faheem President & CEO | Purchase | +372,000 | $0.67 | $250K | 5,408,073 |
| 2024-06-18 | Giraudo Bryan COO/CFO | Purchase | +100,000 | $0.59 | $59K | 480,010 |
| 2024-06-17 | Smith Robert Paul JR Chief Commercial Officer | Purchase | +25,000 | $0.60 | $15K | 25,000 |
| 2024-06-06 | Quisel John D Director | Grant or award · Non-qualified stock option (Right to Buy) | +115,000 | 115,000 | ||
| 2024-06-06 | Milligan Sandra Director | Grant or award · Non-qualified stock option (Right to Buy) | +115,000 | 115,000 | ||
| 2024-06-06 | Cox Russell J. Director | Grant or award · Non-qualified stock option (Right to Buy) | +115,000 | 115,000 | ||
| 2024-06-06 | Daniel Thomas O Director | Grant or award · Non-qualified stock option (Right to Buy) | +115,000 | 115,000 | ||
| 2024-03-27 | Christian Waage EVP, Tech Ops and Admin | Sale | −6,430 | $1.16 | $7K | 585,934 |
| 2024-03-27 | Giraudo Bryan COO/CFO | Sale | −6,430 | $1.16 | $7K | 92,737 |
| 2024-03-27 | Hasnain Faheem President & CEO | Sale | −23,172 | $1.16 | $27K | 120,293 |
| 2024-03-18 | Aranda Richard Chief Medical Officer | Sale | −4,018 | $1.33 | $5K | 198,799 |
| 2024-03-18 | Peterson Caryn EVP, Regulatory Affairs | Sale | −4,018 | $1.33 | $5K | 49,833 |
| 2024-03-11 | Drynan Skye Director | Grant or award · Stock Option (Right to Buy) | +230,000 | 230,000 | ||
| 2024-03-11 | Nathan Steven D Director | Grant or award · Stock Option (Right to Buy) | +230,000 | 230,000 |
Page 9 of 14 · 262 trades